Madhya Pradesh has highest Covid-19 antibodies, Sero Survey data shows

The Central government on Wednesday advised all States and UTs to conduct sero-prevalence surveys in consultation with the Indian Council of Medical Research (ICMR) to generate district-level data.

coronavirus, covid-19, vaccine, vaccination
ANI
2 min read Last Updated : Jul 29 2021 | 9:47 AM IST

The Central government on Wednesday advised all States and Union Territories (UTs) to conduct sero-prevalence surveys in consultation with the Indian Council of Medical Research (ICMR) to generate district-level data.

As per a letter written by the Union Health Secretary to Additional Chief Secretary/Principal Secretary/Secretary (Health) of all States, sero-prevalence survey is essential in formulating localised public health response measures.

"The Union Health Ministry has referred to the findings of the 4th round of National Sero-Prevalence Survey done by ICMR and has advised the States to conduct the sero-prevalence studies in their own States/UTs in consultation with ICMR, so that such studies follow a standardized protocol, and the findings of such studies can then be utilized quickly by the respective State/UT to guide objective, transparent and evidence-based public health response to COVID-19," read the release by the Central government.

ICMR has conducted the recent National Sero-survey in 70 districts of India. The findings of this survey reveal that Madhya Pradesh has the highest seroprevalence with 79 per cent, followed by Rajasthan with 76.2 per cent, Bihar with 75.9 per cent, Gujarat with 75.3 per cent, Chhattisgarh with 74.6 per cent and Uttarakhand with 73.1 per cent.

It further said that the national sero-survey by ICMR was designed to capture the extent of the spread of Covid infection at the national level.

Therefore, the national sero-survey results do not reflect the heterogeneity of sero-prevalence between districts and even between States, read the release.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusMadhya PradeshCoronavirus VaccineCoronavirus TestsICMR

First Published: Jul 29 2021 | 9:47 AM IST

Next Story